Nonuniform dose distributions among disseminated tumor cells can be a significant limiting
factor in targeted α therapy. This study examines how cocktails of radiolabeled antibodies …

Monoclonal antibodies have become a viable strategy for the delivery of therapeutic, particle
emitting radionuclides specifically to tumor cells to either augment anti-tumor action of the …

The use of monoclonal antibodies to deliver radioisotopes directly to tumor cells has
become a promising strategy to enhance the antitumor effects of native antibodies. Since the …

An attractive feature of targeted radionuclide therapy is the ability to select radionuclides and
targeting vehicles with characteristics that are best suited for a particular clinical application …

α-particle radiotherapy has already been shown to be impervious to most resistance
mechanisms. However, in established (ie, large, vascularized) soft-tissue lesions, the …

Alpha-particle radionuclide-antibody conjugates are being clinically evaluated against solid
tumors even when they moderately express the targeted markers. At this limit of lower tumor …

Preclinical studies, in vivo, and in vitro studies, in combination with mathematical modeling
can help optimize and guide the design of clinical trials. The design and optimization of …

Intraperitoneally administered radiolabeled monoclonal antibodies (mAbs) have been tested
in several clinical trials, often with promising results, but have never proven curative …

In this and in the following issues of Cancer, Biotherapy, and Radiopharmaceuticals, we
present a series of articles that were received in our call for papers for a special issue of the …

Targeted α-particle radiation using the radioisotope 225Ac is a promising form of therapy for
various types of cancer. Historic obstacles to the use of 225Ac have been the difficulty in …